Abstract

PurposeThe purpose of this manuscript is to demonstrate that implementation of gravimetric measurements provides the same assurance of product quality and process control as spectroscopic measurements (1) for control of drug content in a fixed-dose combination (FDC) tablet and (2) for identification of non-conforming material.MethodsA wet granulation continuous tableting line was used to make the FDC drug product batches. Comparative data was generated for ten batches using near-infrared (NIR) spectroscopy for core tablets, and gravimetric in-process control measurements (IPCs) applied to the ratio control of intra- and extra-granular blend (IG and EG). HPLC reference data were collected to further demonstrate uniformity at each stage of the production process, including IG, final blend, and core tablets. All possible sources of variation not directly detectable by the gravimetric measurements were considered and quantified.ResultsThe two IPC measurement techniques showed excellent agreement where both were within 2% of the target drug concentrations and within 2% of each other for the ten comparative batches. The NIR was more sensitive to material and process variations than the gravimetric IPCs; thus, it was more variable within and across batches. Gravimetric IPCs were demonstrated as an effective replacement for spectroscopic measurements for continuous tableting operations, capable of ensuring on target manufacturing and detection of non-conforming material.ConclusionsAs pharmaceutical companies continue to push toward operational simplicity and sustainable manufacturing processes, soft-sensor and gravimetric controls as alternatives to their spectroscopic counterparts will be applied more broadly for process monitoring and control.

Highlights

  • Process Description and Control StrategyThe fixed-dose combination (FDC) tablet discussed in this paper is an immediate-release tablet for oral administration containing two active ingredients

  • The CTL-25 is controlled by a qualified and automated process control system which provides for user access control, recipe management, recipe execution, material tracking, data logging, data visualization, and reporting for all integrated unit operations, including alarm logging for parameters outside their respective normal operating limits (NOR) and design space limits (DSL)

  • In order to switch from the direct analytical in-process control measurements (IPCs) measurement of active pharmaceutical ingredients (APIs) concentration to gravimetric IPCs, it was necessary to consider all possible sources of variation not directly detectable by the LIW feeder/load cell measurements

Read more

Summary

Introduction

Process Description and Control StrategyThe fixed-dose combination (FDC) tablet discussed in this paper is an immediate-release tablet for oral administration containing two active ingredients. One of the two active pharmaceutical ingredients (APIs) is a crystalline solid drug substance while the other is an amorphous spray-dried dispersion (SDD) intermediate. The FDC tablet contains 200 mg of crystalline API and 125 mg of SDD and has a total target weight of 565.5 mg. The CTL-25 is controlled by a qualified and automated process control system which provides for user access control, recipe management, recipe execution, material tracking, data logging, data visualization, and reporting for all integrated unit operations, including alarm logging for parameters outside their respective normal operating limits (NOR) and design space limits (DSL). The control scheme for the CTL25 includes configurable recipe-based alarm limits for the NORs and DSLs for process parameters, and all parameters are controlled relative to recipe set points by the automated control system (ACS)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call